OR6K3 CRISPR Activation Plasmid (h): sc-415915-ACT

OR6K3 encodes an olfactory receptor in the class A rhodopsin-like GPCR family, a large receptor group that couples ligand sensing to heterotrimeric G protein signaling. Although best known for roles in odorant detection, olfactory receptors can also be expressed in non-olfactory tissues where they may influence intracellular second messenger dynamics, including cAMP and calcium-dependent signaling. GPCR-driven pathways intersect with transcriptional programs controlling cell state, differentiation, and stress responses, making OR6K3 a useful target for probing receptor-mediated signaling networks. Altered expression patterns of ectopic olfactory receptors have been reported in diverse biological contexts, supporting investigation of OR6K3 as a molecular marker and pathway modulator in human disease-relevant models.

OR6K3 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous OR6K3 expression without altering the underlying DNA sequence.

OR6K3 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the OR6K3 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the OR6K3 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous OR6K3 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native OR6K3 locus and enabling the study of OR6K3-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of OR6K3 pathway restoration in tumor cells with silenced or reduced OR6K3 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.